肝移植术后丙肝复发抗病毒治疗患者持续病毒应答影响因素分析  

Relative factors analysis of sustained viral responses in patients with recurrent hepatitis C infection after liver transplantation

作　　者：李姗霓[1,2] 孙丽莹[2] 朱志军[2] 朱理玮[1] 

机构地区：[1]天津医科大学总医院,天津300192 [2]天津市第一中心医院

出　　处：《山东医药》2010年第50期25-26,共2页Shandong Medical Journal

摘　　要：目的分析肝移植术后丙肝复发抗病毒治疗患者产生持续病毒应答(SVR)的影响因素。方法回顾性分析2003～2009年39例肝移植术后丙肝复发并进行抗病毒(聚二乙醇干扰素和利巴韦林)治疗的患者的临床资料。结果本组中21例因不良反应停药,18例完成全疗程规范治疗,疗程25～105周;有4例(22.22%)获得SVR,其平均治疗周期是57周。统计分析显示,非ⅠB型基因(P=0.023)、治疗前丙肝病毒载量<10~6 copies/ml(P=0.044)以及早期病毒应答(EVR)(P=0.019)与SVR的获得有关。结论非ⅠB基因型、低水平HCV RNA和EVR是肝移植后丙肝复发抗病毒治疗产生SVR的影响因素。Objective To analyz the relative factors analysis of sustained viral responses(SVR) in patients with recurrent hepatitis C infection after liver transplantation.Methods Retrospective analyed The clinical data of 39 patients with hepatitis C recurrence after liver transplantation and antiviral treatment were analized retrospectively.Results 21 patients’ treatment was discontinued due to side effects,18 remaining patients completed a cycle of therapy for 25～105 weeks.The mean treatment duration was 57 weeks with an SVR achieved in 4/18(22.22%).Statistical analysis demonstrate genotype non-IB(P = 0.023),pretherapy RNA<10~6(P = 0.044)and early viral response(P=0.019) were the variables associated with SVR.Conclusion Non IB gene type,low pretherapy RNA and EVR are relative factors affecting SVR on antiviral therapy for recurrence hepatitis C after liver transplantation.

关 键 词：肝移植 丙肝 抗病毒治疗 持续病毒应答 

分 类 号：R657.3[医药卫生—外科学]